Pfizer Reports Plans for Major Boost in Outsourcing, Personnel Cuts
ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer?s restructuring plans reportedly include major investments in outsourced manufacturing operations, production facility closures, and personnel reductions.
Hong Kong (Nov. 30)-Pfizer’s restructuring plans reportedly include major investments in outsourced manufacturing operations, production facility closures, and personnel reductions (Drug Industry Daily, Dec. 3). During an investor meeting in Hong Kong, Martin Mackay, president of Pfizer’s global R&D, said the company is aiming to outsource 30% of its manufacturing activities to lower-cost regions such as Asia, a significant jump from it’s current value of 15%.
According to industry reports, Pfizer plans to close nearly 45 production facilities and reduce its personnel by 10%.
Declining sales stemming from competitive brands and generics, especially for its “Lipitor” (atorvastatin calcium) and “Norvasc” (amlodipine besylate) products, have been cited as the main factors in the company’s need for restructuring.
A webcast and copy of the presentation can be accessed here.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
